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Abstract
Background: Systemic allergic reactions are a risk for allergen immunotherapy that
utilizes intact allergen preparations. We evaluated the safety, efficacy and immune
mechanisms of short-course treatment with adjuvant-free Lolium perenne peptides
(LPP) following a 6-week dose-escalation protocol.
Methods: In a prospective, dose-escalation study, 61 grass pollen–allergic patients
received 2 subcutaneous injections of LPP once weekly for 6 weeks. Safety was
assessed evaluating local reactions, systemic reactions and adverse events. The clini-
cal effect of LPP was determined by reactivity to the conjunctival provocation test
(CPT). Specific IgE, IgG4 and blocking antibodies were measured at baseline (V1),
during (V6) and after treatment (V8).
Results: No fatality, serious adverse event or epinephrine use was reported. Mean
wheal diameters after injections were <0.6 cm and mean redness diameters
<2.5 cm, independent of dose. Transient and mostly mild adverse events were
reported in 33 patients. Two patients experienced a grade I and 4 patients a grade
II reaction (AWMF classification). At V8, 69.8% of patients became nonreactive to
CPT. sIgG4 levels were higher at V6 (8.1-fold, P < .001) and V8 (12.2-fold, P < .001)
than at V1. The sIgE:sIgG4 ratio decreased at V6 (54.6%, P < .001) and V8
(71.6%, P < .001) compared to V1. The absolute decrease in IgE-facilitated aller-
gen binding was 18% (P < .001) at V6 and 25% (P < .001) at V8.
Conclusion: Increasing doses of subcutaneous LPP appeared safe, substantially
diminished reactivity to CPT and induced blocking antibodies as early as 4 weeks
after treatment initiation. The benefit/risk balance of LPP immunotherapy remains
to be further evaluated in large studies.
K E YWORD S
allergen, grass pollen peptides, safety, subcutaneous immunotherapy, tolerability
Abbreviations: AE, adverse event; AWMF, Association of the Scientific Medical Societies in Germany; CPT, conjunctival provocation test; FAB assay, IgE-facilitated allergen binding assay; Ig,
immunoglobulin; ITT, intention to treat; LPP, Lolium perenne peptides formulated for subcutaneous injection; PP, per protocol; SCIT, subcutaneous immunotherapy; sIg, grass pollen–specific
immunoglobulin; SR, systemic allergic reaction; V, visit.
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1 | INTRODUCTION
Conventional allergen injection immunotherapy, based on the con-
cept of tolerance induction,1,2 involves the administration of incre-
mental doses of the sensitizing allergen followed by monthly high-
dose maintenance injections for several years.3 This paradigm, which
is the basis for a personalized medicine approach using “named
patient products” that are still common in the United States and in
parts of Europe, has been shattered during recent years. Regulatory
agencies, such as the German Paul-Ehrlich-Institut and the European
Medicines Agency, regard allergen preparations as therapeutics simi-
lar to synthesized molecules and recommend a classical product
development pathway.4 This concept requires evidence of an optimal
therapeutic dose, which is defined within the framework of efficacy,
tolerability and safety. In this regard, the standard procedures of
developing medicines also have to be applied to immunotherapeutics
containing the prevalent allergens of the homologous groups of
trees, grasses and house dust mites.5 After preclinical tests assuring
quality and harmlessness in terms of toxicology, the 3 classical
phases of the product development route apply.
Lolium perenne peptides immunotherapy has been shown to
have limited IgE binding, basophil and mast cell reactivity and
hence is considered as a safe alternative that can be administered
at higher doses and for a shorter period to improve treatment
adherence.6 Here, we report a proof-of-concept study, which
involved an up-dosing regimen with the primary aim to assess
safety and to identify an individual maximum tolerated cumulative
dose for patients with different statuses of allergen sensitization.
Furthermore, we investigated the immunological effects and a sur-
rogate parameter of clinical efficacy.7
2 | METHODS
2.1 | Approvals and ethics
This study (EudraCT number 2013-000056-18) was approved by the
Independent Ethics Committee (IEC) of the Technical University of
Dresden (IEC number EK 53032013) and by the Paul-Ehrlich-Institut
(PEI) as competent federal authority in Germany. The study was con-
ducted in accordance with local regulations, the International Confer-
ence on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use (International Conference on
Harmonisation (ICH)–Good Clinical Practices (GCP)) and the Declara-
tion of Helsinki.8
2.2 | Study design
This open-label, prospective, dose-escalation study was performed in
grass pollen-allergic patients outside of the grass pollen season.
Patients were required to give written informed consent before
being included in the study. Participants were required to have a
medical history of moderate-to-severe seasonal allergic
rhinoconjunctivitis during the grass pollen seasons of at least the 2
previous years. In addition, a positive skin prick test (wheal diameter
≥3 mm for a grass pollen mixture) and grass pollen–specific IgE (sIgE)
antibodies >0.7 kU/L were necessary for study inclusion (see Data
S1 for further inclusion and exclusion criteria).
The study was carried out in the outpatient allergy clinic of the
Department of Oto-Rhino-Laryngology at the University Hospital
Carl-Gustav-Carus (Dresden, Germany) and consisted of 8 visits: 1
screening visit (V1), 6-weekly treatment visits (V2–V7) and 1 follow-
up visit (V8), which took place 1–2 weeks after V7. The patients
received 12 subcutaneous injections of increasing doses of LPP in
form of a cluster scheme.9 At each treatment visit (V2–V7), 2 injec-
tions of equal peptide dose were administered 30 minutes apart,
one in each arm. After the second injection, patients remained under
observation at the trial site for a further 30 minutes. Dose escalation
started with a total LPP dose of 10 lg administered at V2 and
increased to 20 lg at V3, 40 lg at V4, 80 lg at V5, 140 lg at V6
and 200 lg at V7, resulting in a cumulative dose of 490 lg.
2.3 | Formulation of the Lolium perenne peptides
(LPP)
Based on the extensive immunological cross-reactivity among grass
pollens belonging to different species, Lolium perenne (L. perenne)–
derived allergens are considered appropriate for the treatment of
IgE-mediated grass pollen allergy in general.10 Briefly, L. perenne pro-
teins were extracted from a natural source to obtain a crude extract,
which was then purified of nonprotein components. The proteins
were then denatured and enzymatically hydrolysed to generate pep-
tides of 1000–10 000 Da.6 The LPP were supplied in ready-to-use
vials with a ryegrass pollen peptide concentration of 100 lg/mL in
1.5 mL aqueous-buffered solution (pH 7.4). The formulation con-
tained no adjuvant.
2.4 | Administration site reactions, safety
considerations
Local reactions after subcutaneous immunotherapy (SCIT) are com-
mon and may be accompanied by swelling, tenderness and occa-
sional discomfort. Early reactions >5 cm are an indication for dosage
adjustment, and large late local reactions may be a source of discom-
fort and inconvenience to patients. For this reason, we made objec-
tive measurements of early skin reactions at 30 minutes and late
reactions up to 48 hours. The local reaction diameters (wheal and
redness at the injection site) were recorded by the investigator
30 minutes after the injections and by the patients after 8 hours
and in the evenings of day 1 and day 2 after injection.
All local symptoms at the injection site other than wheal and
redness or systemic AEs were reported as unsolicited AEs and were
coded according to the Medical Dictionary for Regulatory Activities
(MedDRA, version 16.1). Systemic allergic reactions (SRs) emerging
after an injection were graded appropriately as stage I to stage IV
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according to the recommendations of the Association of the Scien-
tific Medical Societies in Germany (AWMF: Arbeitsgemeinschaft der
Wissenschaftlichen Medizinischen Fachgesellschaften e.V.).11
According to the protocol, if a wheal diameter measuring 5–8 cm
appeared within 30 minutes after an injection or if an SR grade I
occurred (AWMF classification), the same dose had to be repeated
at the following injection. If a wheal diameter was >8 cm 30 minutes
after an injection or if an SR grade II occurred, the dose was reduced
by one step at the next injection. Patients were to be excluded from
further participation to study treatment if an SR grade III or IV
occurred.
2.5 | Reactivity to the conjunctival provocation test
(CPT)
As a secondary endpoint, the CPT was used as a surrogate marker
for the assessment of the clinical effects of the LPP treatment. The
CPT was performed at V1, V6 and V8 using the allergen extract
ALK-lyophilized SQ (ALK-Abello, Hamburg, Germany) with standard-
ized units (SQ-E/mL).12 The stock solution consisted of 100 000 SQ-
E/mL and was extemporaneously diluted to 10 000, 1000 and
100 SQ-E/mL. The test procedure was performed and evaluated
according to the CPT protocol described by Riechelmann et al13 and
was considered positive if the response was stage II or higher. The
CPT score was calculated as 0 = no reaction at all, 1 = reaction at
10 000 SQ-E/mL, 2 = reaction at 1000 SQ-E/mL and 3 = reaction
at 100 SQ-E/mL.
2.6 | Allergen-specific immunoglobulin and blocking
antibody production
Specific IgE and IgG4 levels for 5 grasses (Anthoxanthum odoratum,
Lolium perenne, Phleum pratense, Secale cereale and Holcus lanatus)
were measured in serum at V1, V6 and V8 using the ImmunoCap
method (Pharmacia Diagnostics AB, Uppsala, Sweden). The IgG-
associated blocking antibodies were measured by FAB assay10,14,15
(see Data S1 for detailed description).
2.7 | Statistical analysis
The statistical analysis was performed using IBM SPSS Statistics for
Windows (version 22.0, IBM Corp., Armonk, NY, USA) and consisted
of descriptive statistics including the mean and standard error of the
mean (SEM). Changes in sIgE and sIgG4 levels between V1 and V6
were analysed using the Friedman signed rank test, taking into
account correction for multiple comparison. A P < .05 was consid-
ered providing the statistical significance threshold.
3 | RESULTS
3.1 | Demographic data and baseline values
Overall, 88 patients were screened. Of these, 20 patients did not ful-
fil the inclusion criteria or met at least one of the exclusion criteria,
and 3 patients withdrew their consent (Figure 1). The intention-to-
F IGURE 1 CONSORT flow chart of the
study population
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treat analysis set (ITT set) included the patients who had completed
at least one treatment visit and for whom the safety parameters had
been documented. Four more patients had already received their
first injection when a delayed laboratory analysis showed that they
were ineligible. By consequence, they were excluded from further
treatment. The safety population consisted of 65 patients, 61 of
whom constituted the ITT set. The per-protocol set included 53
patients.
Patients in the ITT set had a medical history of seasonal allergy
to grass pollen with a mean duration of 20.6 years
(range: 3–58 years) (Table 1). Skin prick tests for grass pollen
showed a mean wheal diameter of 6.3 mm (range: 4–15 mm). The
mean sIgE level at baseline was 38.2 kU/L (range: 1.0–101.0 kU/L).
3.2 | Conjunctival provocation test (CPT)
The clinical effects of LPP were analysed using the surrogate
parameter CPT. At baseline, a positive reaction was documented
for 19.2% of patients at 100 SQ-E/mL, 53.8% of patients at
1000 SQ-E/mL and 26.9% of patients at 10 000 SQ-E/mL
(Figure 2A). At V6, reactivity to the CPT was lower than that at
baseline in 83% of patients. Most of the patients (67.3%) did not
react at all to the CPT, and 25.0% of the patients reacted at the
10 000 SQ-E/mL level. At V8, CPT reactivity was decreased com-
pared to baseline in 87.5% of the patients, and 69.8% of patients
did not react to provocation at all. Fifteen patients (28.3%)
reacted to the highest concentration of 10 000 SQ-E/mL, and only
one patient (1.9%) reacted to 1000 SQ-E/mL. None of the
patients reacted to 100 SQ-E/mL at V8. The improvement was
also reflected by the change in the CPT score (Figure 2B). The
mean CPT score was significantly lower at V6 (P < .001) and V8
(P < .001) than at V1. These findings are supported by the objec-
tive measurements of conjunctival redness using digital image
analysis.16 Figure 3 depicts the reduction in the proportion of red
pixels in the region of interest as a sign of decreased conjunctival
vasodilation.
3.3 | Safety
Fifty-three patients (86.9%) reached the target cumulative dose of
490 lg of LPP. No fatality or any other serious AE was reported
during the study.
Thirty minutes after all LPP injections, mean wheal diameters at
the injection site were well below the 5-cm threshold,17 varying
from 0.36 to 0.53 cm, independent of the LPP dose injected (5–
100 lg) (Figure S1). The largest wheal diameter was 3.5 cm. Mean
wheal diameters 8 hours after injections were somewhat larger
(range: 0.43–0.75 cm) and decreased slightly 1 day after injections
(range: 0–0.24 cm). Two days after injections, mean wheal diameters
ranged from 0 to 0.12 cm. Only 4 patients experienced a wheal
reaction greater than 5 cm at some time. Also, 97.8% of reactions
reported in diary cards were mild (<5 cm), 2% were moderate (5–
8 cm), and 0.2% were severe (>8 cm, with a maximum of 9.5 cm
observed 8 hours after injection).
The mean redness diameters reported 30 minutes after injections
were less than 2.3 cm throughout the study, with individual values
TABLE 1 Patient demographics
Patients (N = 61)
Age (y), mean  SD 36.0  9.3 years
Gender, n (%)
Male 40 (65.6)
Female 21 (34.4)
Disease duration (y), mean (range) 20.6 (3–58)
Grass pollen-specific IgE
IgE serum level (kU/L), mean (range) 38.2 (1–101)
CAP class, mean (range) 4 (2–6)
Skin prick pest to grass pollen (mm), mean (range) 6.3 (4–15)
CAP, carrier polymer system; Ig, immunoglobulin; SD, standard deviation.
Values are for the intention-to-treat (ITT) set.
F IGURE 2 Effects of LPP immunotherapy on CPT reactivity and CPT scores (ITT set). (A) Proportion of reactive patients to CPT in
response to 100, 1000 and 10 000 SQ-E/mL of grass pollen allergen extract at V1, V6 and V8. No Rxn represents patients nonreactive at
10 000 SQ-E/mL. Data are expressed as percentage of reactive patients. (B) Development of CPT score. Data are expressed as mean  SEM,
P < .001 compared to V1. CPT, conjunctival provocation test; ITT, intention to treat; LPP, Lolium perenne peptides formulated for
subcutaneous injection; SEM, standard error of the mean; SQ-E, standardized quality units; V, visit
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ranging from 0 to 8.00 cm independent of the dose. Reactions were
transient. Mean redness diameters increased slightly with time during
the injection day (3.18 cm; maximum: 15.50 cm) and then decreased
to less than 1.75 cm on day 1 and <0.5 cm on day 2 after injection.
Overall, AEs occurred in 33 patients. Furthermore, 83% of the
AEs were considered related or possibly related to the study medica-
tion. The majority of AEs (96%) were classified as mild and 4% as
moderate (one grade II reaction and one event of swelling of the
upper arm were considered treatment-related). All AEs resolved
spontaneously (32.1% of AEs) or with antihistamines and one case
with a beta-agonist. No use of epinephrine or oral/IV steroid was
reported. AEs related to treatment occurring in at least 5% of the
patients are presented in Table S1. The most frequently reported AE
was injection site pruritus (21.5% of patients).
Six patients (9.2%) experienced at least one SR (coded as hyper-
sensitivity in Table S1). Two patients experienced an SR of grade I
(AWMF classification), characterized by flushing of the face in the
first patient and by pressure in the ears, facial erythema and itching
of the mouth in the second patient. Four patients (6.2%) experienced
SRs of grade II. The SRs included one case of facial flushing with
nasal mucosa swelling (resolved with cetirizine and xylometazoline
spray), one case of respiratory symptoms accompanied by eye red-
ness (resolved with cetirizine) and one event of cough (treated with
cetirizine). Another patient developed a first SR of grade II after
receiving 10 lg of LPP (erythema, skin warmth and rhinorrhoea,
treated with cetirizine). As defined in the protocol, the patient
received 5 lg of LPP per injection at the next visit and tolerated it
well. The patient experienced respiratory problems (SRs of grade II,
treated with fenoterol) after receiving 10 lg of LPP, resulting in the
discontinuation of treatment (as per protocol). All SRs occurred
within 30 minutes after injection, except for one event of respiratory
symptoms with eye redness that occurred 1 hour after injection, and
all resolved within a few hours. No SR of grade III and IV was docu-
mented.
3.4 | Immunogenicity
Specific IgE levels to grass pollen were increased at V6 (P < .001)
and at V8 (P < .001) compared to V1 (Figure 4A) but to a lesser
extent than sIgG4 serum levels (8.0-fold increase at V6 [P < .001]
and 12.2-fold increase at V8 [P < .001]) (Figure 4B). Consequently,
the sIgE:sIgG4 ratio decreased from V1 to V6 (P < .001) and from
V1 to V8 (P < .001) (Figure 4C). Treatment with LPP also induced a
significant production of specific IgG (P < .001) but had no effect on
IgA (data not shown). Serum inhibitory activity for IgE-FAB was
assessed using the FAB assay. The values for the mean relative IgE-
allergen complex binding to B cells were lower at V6 (P < .001) and
at V8 (P < .001) than at V1. The absolute decreases for IgE-FAB
were 18% (V6) and 25% (V8) (Figure 5A). Moreover, the change
from baseline in the FAB value was strongly associated with specific
IgG4 at V6 (Spearman rank correlation coefficient: r = .56, P < .001)
and V8 (r = .45, P = .001) (Figure 5B).
4 | DISCUSSION
In this study, we show for the first time that the use of hydrolysates
of LPP escalated to a maximum cumulative dose of 490 lg was well
tolerated (86.9% of the patients reached this target dose), eliciting
only minimal early local and late skin responses. There were a few,
mostly mild, systemic reactions to these high-dose allergen injections
that required either no treatment or responded well to oral antihis-
tamines and, in a single case, inhaled fenoterol. No serious adverse
drug reactions, no anaphylactic reactions and no use of epinephrine
were reported throughout the study. The overall good safety profile
can be explained by the ex vivo characteristics of LPP (limited IgE
binding, basophil and mast cell reactivity).6 There was a marked and
consistent reduction in the immediate conjunctival response to
whole allergen extract and an increase in functional specific IgG
antibodies.
Local reactions at the injection site represent a relevant parame-
ter when addressing the safety of grass pollen SCIT. Thirty minutes
after the injections, all mean wheal diameters were mild (below the
5-cm threshold)17 and transient, highlighting the overall good safety
profile of the LPP treatment administered in such a cluster schedule.
Wheals were accompanied by a small area of redness. Mean wheal
and redness diameters increased slightly 8 hours after the injection,
and a few patients reported moderate/severe local reactions.
Although inconvenient, delayed (6–12 hours) local reactions are not
regarded as an increased risk for SRs.18 The safety and tolerability of
the LPP treatment appear to be better than those reported for an
ultra-short up-dosing scheme with a 6-grass mix and rye allergen
F IGURE 3 Digital analysis of the percentage of red pixels in the
conjunctival region of interest (ROI) in patients undergoing
conjunctival allergen challenge before (V1), during (V6) and after (V8)
LPP immunotherapy (ITT set). Rmax is the percentage of red pixels in
the ROI following the maximum tolerated allergen concentration.
ITT, intention to treat; LPP, Lolium perenne peptides formulated for
subcutaneous injection; RMS, root mean square
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extract performed in-season.19 In that study, wheal diameters rang-
ing from 5 to 20 cm (11.9%) and even larger than 20 cm (0.3%)
were observed 30 minutes after injection. The high local reactivity
reported by the authors could be explained by the fact that product
administration was performed during the pollen season.20,21
The analysis of the occurrence of SRs (9.2% of patients and
0.9% of injections, no grade III or grade IV SR) also suggests that
LPP has a safety profile comparable to that of conventional SCIT,
although a direct comparison is difficult due to differences in study
designs and populations. A Cochrane meta-analysis of data on SCIT
products used in 51 clinical studies showed that SRs occurred in
19% of patients.2
In a randomized, dose-ranging, safety study performed with
recombinant Phleum grass pollen allergens absorbed to aluminium
hydroxide, treatment-related SRs were reported in 16% of all
patients and in 2.2% of all injections.22,23 As observed with LPP, Kli-
mek et al22 did not detect a relation between the frequency of the
SR and the increase in the injected dose. LPP may also have a safer
profile than that of the Alutard grass pollen product, as SRs were
reported for 32.5% of patients treated with 100 000 SQ-U Alutard
F IGURE 4 sIgE, sIgG4 and sIgE:sIgG4
ratio responses following LPP
immunotherapy. (A) Induction of grass
pollen–specific IgE; (B) sIgG4 mean levels;
and (C) sIgE:sIgG4 ratio from V1 to V8 in
patients treated with increasing doses of
grass pollen peptides (ITT set). Data are
presented as mean  SEM, P < .001
compared to V1. Ig, immunoglobulin; ITT,
intention to treat; LPP, Lolium perenne
peptides formulated for subcutaneous
injection; SEM, standard error of the mean;
sIg, specific immunoglobulin; V, visit
F IGURE 5 LPP peptide immunotherapy induces functional antibody responses that are closely associated with IgG4 (ITT set). (A) Ag-IgE
complexes binding to B cells were assessed by IgE-FAB assay using 0.3 lg/mL Phl p at V1, V6 and V8. Data are expressed as mean  SEM,
P < .001 compared to V1. (B) The change from baseline for Ag-IgE complexes binding to B cells was closely correlated with the change from
baseline for sIgG4. Spearman rank correlation coefficient r = .452, P < .05 was considered significant. Ag, allergen; FAB, facilitated allergen
binding; Ig, immunoglobulin; ITT, intention to treat; LPP, Lolium perenne peptides formulated for subcutaneous injection; Phl p, Phleum pratense;
SEM, standard error of the mean; V, visit
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and for 21.2% patients in the 10 000 SQ-U group. Moreover, 9 non-
life-threatening reactions of grade III (according to the EAACI classifi-
cation) were observed.24 In a more recent study, 7.1% of the patients
experienced SRs following an ultra-short up-dosing schedule with
Alutard SQ up to the maintenance dose of 10 000 SQ-U.19 SRs
were also observed in 5.6% of the placebo group patients. The fre-
quency of SRs reported by these authors is similar to the one
observed here with LPP; however, no information on the severity of
the SRs can be deduced from their study.19 As mentioned earlier, SRs
occurred in 0.9% of all injections in the present study. This is much
lower than the frequency observed with the depot allergoid Pure-
thal (4.3%)25 or with other SCIT products (reviewed in Ref26,27) and
similar to the data reported after a conventional administration
schedule with a 5-grass recombinant allergen mixture (0.98%).28
Although these data showed an overall good safety profile for
LPP, they were obtained in a limited number of patients and need to
be confirmed in larger studies.
Besides assessing the safety of LPP treatment, the CPT surrogate
marker was used to follow up on the clinical status of the patients.
Conjunctival provocation has been shown to be a reliable method
for diagnosing allergy and for evaluating the clinical effect of
immunotherapy products, especially if digital image analysis is
used.7,16 A decrease in CPT reactivity from baseline was observed in
83% (V6) and 87.5% (V8) of patients. In addition, most of the
patients (67.3%) no longer reacted at all to the CPT at V6. No fur-
ther reduction in CPT reactivity was found at V8 (69.8%). The objec-
tive assessment of conjunctival vasodilation using digital image
analysis was in line with the findings of the investigators. These data
are similar to those of Klimek et al,22 although the studies are not
directly comparable due to the different CPT provocation solutions
and methodology used.
We acknowledge the limitation of this study due to the lack of a
placebo arm. Nonetheless, these results clearly suggest a significant
therapeutic effect can be observed after only 4 weeks of treatment
and the administration of a cumulative dose of 150 lg of LPP.
As a secondary outcome, the immunological effect of LPP treat-
ment was analysed by measuring sIgE and sIgG4 levels as well as the
production of functional blocking antibodies. Specific IgE increased
during the course of the study (1.7-fold). Some studies postulated
that an increase in sIgE levels following SCIT might be associated
with an increased risk of systemic AEs.29,30 With regard to the ratio
of SRs to injections and the small (although statistically significant)
increase in sIgE levels presented here, the number of SRs was not
higher than that reported in other studies.2,19-28
As reported previously,6 we observed a stronger induction of
sIgG4 as early as 4 weeks after the initiation of treatment, with a
further increase following treatment completion. This resulted in a
shift of the sIgE:sIgG4 ratio towards the induction of tolerance.
These data, especially the induction of sIgG4, concur with those of
previous studies investigating conventional and short-course adju-
vant-containing SCIT and sublingual immunotherapy.31-33 The desir-
able immunological effects, which are similar to those of
conventional long-term SCIT treatment, elucidate the mechanisms of
action of LPP. Moreover, to our knowledge, LPP is the first peptide
preparation which induces the production of blocking antibodies
against allergens as measured by a functional bio-cellular assay.15 No
other studies performed with peptides have demonstrated the induc-
tion of protective blocking antibodies following treatment.34,35
In summary, the short-course cluster treatment with the adju-
vant-free LPP formulation investigated here showed an overall good
safety and tolerability profile, with virtually no local pain, discomfort
or swelling following injections being reported. LPP also elicited a
positive immune effect and a clinical effect in seasonal allergic rhini-
tis patients. Larger studies are of course needed to confirm the
safety and efficacy of cluster treatment with LPP, starting with a
randomized, double-bind, placebo-controlled dose-finding study.
However, the favourable data reported here suggest that LPP might
lead to improved patient compliance and ultimately to improved
efficiency.
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